ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07618
-0,10%
Bitcoin
63.733,89
-0,25%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Myriad Genetics Inc (MYGN)

  7. Myriad Genetics Inc (MYGN) News

MYGN Myriad Genetics Inc

19,43
0,21 (1,09%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Myriad Genetics Inc MYGN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,21 1,09% 19,43 23:58:41
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
19,85 19,40 20,09 19,47 19,22
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202422:05GLOBEMyriad Genetics to Release First Quarter 2024 Financial..
17.4.202414:00GLOBENearly Half of Americans Say They’ve Lost Time in Their..
16.4.202415:15GLOBENew Myriad Genetics Study Published in Prenatal Diagnosis..
09.4.202414:00GLOBEMyriad Genetics Research Shows Reduction in Hospitalizations..
22.3.202402:40GLOBEMyriad Genetics Announces Foundational Patent Granted for..
20.3.202421:05GLOBEMyriad Genetics Announces Patent Granted for SneakPeek® Snap..
04.3.202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202414:31EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27.2.202422:05EDGAR2Form 8-K - Current report
27.2.202422:05GLOBEMyriad Genetics Reports Strong Fourth Quarter and Full-Year..
27.2.202415:15GLOBEMyriad Genetics and National Cancer Center Hospital East in..
26.2.202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202422:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.2.202422:05GLOBEMyriad Genetics to Release Fourth Quarter and Full Year 2023..
15.2.202422:05GLOBEMyriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as..
14.2.202422:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202414:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.2.202416:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01.2.202415:25GLOBEMyriad Genetics Completes Acquisition of Precise Tumor,..
31.1.202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.1.202423:00GLOBEMyriad Genetics Names George Daneker Jr., MD, as President..
29.1.202422:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.1.202422:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
23.1.202422:31EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22.1.202420:03EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19.1.202400:10GLOBEMyriad Genetics to Acquire Precise Tumor, Precise Liquid and..
16.1.202415:00EDGAR2Form 8-K - Current report
09.1.202422:05GLOBEMyriad Genetics Applauds New Germline Testing Guideline for..
03.1.202422:05GLOBEMyriad Genetics to Present at 42nd Annual J.P. Morgan..
02.1.202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.12.202314:30EDGAR2Form 8-K - Current report
21.12.202314:30GLOBEMyriad Genetics Chief Financial Officer Bryan Riggsbee..
20.12.202314:00GLOBEMyriad Genetics Establishes Comprehensive Pan-Cancer..
12.12.202300:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12.12.202300:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
05.12.202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20.11.202322:05GLOBEMyriad Genetics Celebrates One Million SneakPeek® Results..
16.11.202322:05GLOBEMyriad Genetics and Personalis Partner to Market..
13.11.202322:31EDGAR2Form 8-K - Current report
13.11.202312:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09.11.202313:00GLOBEMyriad Genetics to Participate in Stephens Annual Investment..
09.11.202303:20GLOBEMyriad Genetics Announces Pricing of Upsized Offering of..
09.11.202303:16EDGAR2Form 8-K - Current report
08.11.202322:10GLOBEMyriad Genetics Announces Proposed Offering of $100 Million..
08.11.202322:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08.11.202322:01EDGAR2Form S-3ASR - Automatic shelf registration statement of..
07.11.202314:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06.11.202322:05EDGAR2Form 8-K - Current report
06.11.202322:05GLOBEMyriad Genetics Reports Third Quarter 2023 Financial..
03.11.202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Kürzlich von Ihnen besucht

NASDAQ
MYGN
Myriad Genetics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten